Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Moxalactam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.80 |
| ▸ | CMA1 | P23946 | 18/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moxalactam SCHEMBL49016 | 1.00 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL14196602 | 1.00 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL194013 | 1.00 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL49017 | 1.00 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL951857 | 0.99 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL10694935 | 0.99 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL584454 | 0.99 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL951858 | 0.99 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL9800360 | 0.99 | PTGS1 (0.97) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL3382938 | 0.93 | PTGS1 (0.87) | PTGS1HSD17B10TDP1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5128 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637481-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2026-05-26 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12590108-B2 | Boracic acid compound | PHAENO THERAPEUTICS CO., LTD (CN) | 2026-03-31 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | RECREO PHARMACEUTICALS LLC (US) | 2025-07-29 | — | — | US | claimed |
| US-20250222118-A1 | Beta-Lactam-Cannabinoid Conjugate Molecules | DIVERSE BIOTECH INC (US) | 2025-07-10 | — | — | US | claimed |
| US-20250099557-A1 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | SHANGHAI BAO PHARMACEUTICALS CO., LTD. (CN) | 2025-03-27 | — | — | US | claimed |
| US-4762720-A | Process for preparing liposome compositions | SHIONOGI & CO., LTD. (JP) | 1988-08-09 | — | — | US | claimed |
| CN-87106855-A | The manufacture method of composition for oral liquid | — | 1988-04-20 | — | — | CN | claimed |
| EP-0036534-B1 | AN ORALLY ADMINISTRABLE DRUG FORM COMPRISING A BETA-LACTAM ANTIBIOTIC AND AN ADJUVANT | INTERx RESEARCH CORPORATION (US) | 1987-09-23 | — | — | EP | claimed |
| EP-0236074-A1 | 2Beta-substituted thiomethylpenicillin derivatives and their preparation and use | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1987-09-09 | — | — | EP | claimed |
| US-H328-H | Purification of cephalosporins | SHIONOGI & CO., LTD. (JP) | 1987-09-01 | — | — | US | claimed |
| EP-0138523-B1 | PENICILLIN DERIVATIVES AND PROCESS FOR PREPARING THE SAME (11111) | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1987-08-19 | — | — | EP | claimed |
| US-4668514-A | Penicillin derivatives | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1987-05-26 | — | — | US | claimed |
| US-4562073-A | BETA-LACTAMASE INHIBITORS | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1985-12-31 | — | — | US | claimed |
| US-4529592-A | Substituted in position 2 with a (4,5-diester-1,2,3-triazol-3-yl)alkyl group | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1985-07-16 | — | — | US | claimed |
| EP-0138523-A1 | Penicillin derivatives and process for preparing the same (11111) | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1985-04-24 | — | — | EP | claimed |